Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability

Emily Tam, Andrea D Furlan, Emily Tam, Andrea D Furlan

Abstract

Background: Acute neuropathic pain is a common disorder. Transdermal cream could be an alternative to oral medications.

Objective: To evaluate the effectiveness and tolerability of transdermal Lidocaine and Ketamine for acute neuropathic pain.

Study design: Retrospective chart review

Setting: University-affiliated outpatient Physiatry clinic

Methods: ARTICIPANTS: neuropathic pain with a prescription of a transdermal cream containing Lidocaine and Ketamine. Ef-fectiveness was evaluated by the number of patients with improvement divided by the total number of patients who re-ceived a prescription of the cream.

Results: A total of 854 patient charts were reviewed. Twenty-one patients with symptoms, signs, and/or a documented di-agnosis of neuropathic pain and had been given a prescription of a transdermal preparation containing Lidocaine and Ketamine. Four groups were identified: those with a clearly stated diagnosis of neuropathic pain and prescribed a transdermal compound containing Lidocaine and Ketamine with follow-up (Group A) or without follow-up (Group B), and those with a suggested diagnosis of neuropathic pain with (Group C) or without follow-up (Group D). Effectiveness of the cream was seven out of eight (87%) for Group A and one out of three (33%) for Group C. In total, eight out of 11 patients (73%) benefited from a cream containing Lidocaine and Ketamine. Two patients experienced skin reactions that led to discontin-uation of treatment.

Limitations: This is a retrospective chart review without control group.

Conclusion: Transdermal cream containing Ketamine and Lidocaine was effective in 73% of patients with acute neuro-pathic pain and may be a good alternative to oral medications.

Keywords: Transdermal; ketamine; lidocaine; neuropathic pain..

Figures

Fig. (1)
Fig. (1)
Age range of patients.
Fig. (2)
Fig. (2)
Underlying diagnoses contributing to neuropathic symptoms.
Fig. (3)
Fig. (3)
Concomitant Use of Medications for Neuropathic Pain.
Fig. (4)
Fig. (4)
Components of Transdermal Creams Prescribed.
Fig. (5)
Fig. (5)
Body Parts Affected by Neuropathic Pain.

References

    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7:281–9.
    1. Moulin DE, Clark AJ, Gilron I. Pharmacological management of chronic neuropathic pain - Consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13–21.
    1. Gilron I, Watson CPN, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. CMAJ. 2006;175:265–75.
    1. Vadaurri V. Topical treatment of neuropathic pain. Int J Pharm Compd. 2008;12:182–90.
    1. Sawynok J. Topical and peripherally acting analgesics. Pharmacol Rev. 2003;55:1–20.
    1. Jovey RD, editor. Second. Toronto: Healthcare & Financial Publishing; 2002. Managing pain: the Canadian healthcare professional's reference.
    1. Woolf CJ. Pain: Moving from symptom control toward mecha-nism-specific pharmacologic management. Ann Intern Med. 2004;140:441–51.
    1. de Leon-Casasola OA. Multimodal approaches to the management of neuropathic pain: the role of topical analgesia. J Pain Symptom Manage. 2007;33:356–64.
    1. Woolf CJ. Central sensitization: uncovering the relation between pain and plasticity. Anesthesiology. 2007;106:864–7.
    1. Dworkin RH, O'Connor AB, Backonja M, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132:237–51.
    1. Ball AM, Smith KM. Optimizing transdermal drug therapy. Am J Health Syst Pharm. 2008;65:337–46.
    1. McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. Br J Clin Pharmacol. 2000;49:574–9.
    1. Murdan S. A review of pluronic lecithin organogel as a topical and transdermal drug delivery system. Hosp Pharm. 2005;12:267–70.
    1. Sandoval JA, Furlan AD, Mailis-Gagnon A. Oral methadone for noncancer pain. Clin J Pain. 2005;21:503–12.
    1. Lynch ME, Clark AJ, Sawynok J, Sullivan MJL. Topical 2% amitriptyline and 1% ketamine in neuropathic pain syndromes. Anesthesiology. 2005;103:140–6.
    1. Ho K-Y , Huh BK, White WD, Yeh C-C, Miller EJ. Topical amitriptyline versus lidocaine in the treatment of neuropathic pain. Clin J Pain. 2008;24:51–5.
    1. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106:151–8.
    1. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007;Art. No.: CD004846(Issue 2) DOI: 10.1002/14651858.CD004846.pub2.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa